August 14, 2018
Show me the “upside” or was it, the meatballs!
Earnings: Biostage (BSTG) reports Q2 – a whole lot of nothing and short “runway”!
RMi reports pre-open indications that shed light on share pricing events and today’s session values.
When is it wrong to be right so often?
Your portfolio should be profiting from RMi’s analysis -SUBSCRIBE!
August 11, 2018
Q2/18 financial results also known as (AKA) earnings is a ‘scorecard’ of public stem, cell, gene therapies and editing, regenerative therapy and a couple of CNS and RNAi companies
Twenty-nine (29) LPS, four (4) net income and one (1) delay - Intrexon (XON) ... so far
The current LPS (loss per share) standings reflect the universes’ investing status; then add in their cash position and "runways" for a better snapshot!
By analyzing these comparisons, investors can begin to gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.
August 13, 2018
Risks to the market spilled over into the sector
Pre-open indications: 1 hit
Out and about: MiMedx Group (MDXG) has been granted a hearing request for a listing extension. This allows for the continued trading of MDXG's stock on the NASDAQ until its determination on 9/13/18. There can be no assurance that the Panel will grant MDXG's request!
What’s going on with some analyst recommendations? I-Bank research is a motivation to buy a stock and once in a blue moon, when to sell.
RMi’s independent analysis is NOT “married” to any equity; like it or not - a trusted source of factual reporting. A BUY or a SELL can change in hours in our research notes!
Subscribe!
August 8, 2018
RGNX closed down -$0.25 to $70.55 with an aftermarket downside of -$0.45 or -0.64% - SELL After reporting Q2 net income of $10.6 M or a profit of $0.30 per share; earnings, adjusted for non-recurring gains, were $0.15 per share.
July 25, 2018
BLUE had closed down -$13.60 to $163.65after Monday's -$3.10 to $177.25 and is down another -$0.65 or -0.40% – Maintaining SELL; The estimated proceeds are approximated at $550 M aith an overalottment of 507,692 shares Goldman Sachs & Co. LLC, BofA Merrill Lynch, J.P. Morgan Securities LLC and Cowen are acting as joint book-running managers and Wells Fargo Securities is acting as co-manager of the proposed offering.
July 24, 2018
CRSP (-$6.33 or -11.05%), EDIT (-$2.89 or -8.17%) and NTLA (-$2.89 or -8.17%) at Tuesday’s mid-day Yet another “shuffle” to the downside… as I had stated, it ain’t over … falling precipitously in the day’s range!
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
© 2018 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
